enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Biogen-UCB's lupus drug meets main goal of late-stage trial - AOL

   www.aol.com/news/biogen-ucbs-lupus-drug-meets...

   The drug is being tested in patients with the most common form of lupus, systemic lupus erythematosus, where the patient's immune system attacks the body's own tissues and potentially leads to ...

3. Biogen Gains Momentum With Positive Lupus Drug Results ... - AOL

   www.aol.com/finance/biogen-gains-momentum...

   On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...

4. What is lupus and how is it treated? - AOL

   www.aol.com/news/lupus-treated-020821382.html

   A new treatment is being trialled for the autoimmune condition

5. Anifrolumab - Wikipedia

   en.wikipedia.org/wiki/Anifrolumab

   Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.

6. Litifilimab - Wikipedia

   en.wikipedia.org/wiki/Litifilimab

   Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti- BDCA2 monocolonal antibody. [ 1 ] [ 2 ] [ 3 ]

7. Efavaleukin alfa - Wikipedia

   en.wikipedia.org/wiki/Efavaleukin_alfa

   Efavaleukin alfa is an experimental drug that works as an interleukin-2 "mutein Fc fusion protein that preferentially binds the high-affinity IL-2 receptor alpha chain to selectively promote Treg expansion". [1] It is developed to treat systemic lupus erythematosus (SLE). [2] [3] [4]

8. AstraZeneca lupus drug shows promise after set-back last year

   www.aol.com/news/astrazeneca-lupus-drug-meets...

   The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final ...

9. Obexelimab - Wikipedia

   en.wikipedia.org/wiki/Obexelimab

   Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells , plasmablasts , and CD19-expressing plasma cells ."